Abstract: Here, we applied the designed ankyrin repeat protein (DARPin) technology to develop novel gp120-directed binding molecules with HIV entry-inhibiting capacity. DARPins are interesting molecules for HIV envelope inhibitor design, as their high-affinity binding differs from that of antibodies. DARPins in general prefer epitopes with a defined folded structure. We probed whether this capacity favors the selection of novel gp120-reactive molecules with specificities in epitope recognition and inhibitory activity that differ from those found among neutralizing antibodies. The preference of DARPins for defined structures was notable in our selections, since of the four gp120 modifications probed as selection targets, gp120 arrested by CD4 ligation proved the most successful. Of note, all the gp120-specific DARPin clones with HIV-neutralizing activity isolated recognized their target domains in a conformation-dependent manner. This was particularly pronounced for the V3 loop-specific DARPin 5m3 D 12. 
antibodies. DARPins in general prefer epitopes with a defined folded structure. Here we probed 30 whether this capacity favors the selection of novel gp120--reactive molecules with specificities 31 in epitope recognition and inhibitory activity that differ from those found amongst neutralizing 32 antibodies. The preference of DARPins for defined structures was notable in our selections as of 33 the four gp120 modifications probed, gp120 arrested by CD4 ligation proved the most 34 successful panning target. Of note, all gp120 specific DARPin clones with HIV neutralizing 35 activity we isolated, recognized their target domains in a conformation--dependent manner. 36 This was particularly pronounced for the V3--loop--specific DARPin 5m3_D12. In stark contrast to 37 V3--specific antibodies, 5m3_D12 preferentially recognized the V3 loop in a specific 38 conformation, as probed by structurally arrested V3 mimetic peptides, but bound linear V3 39 peptides only very weakly. Most notably, this conformation--dependent V3 recognition allowed 40 5m3_D12 to bypass V1V2 shielding of several tier 2 HIV isolates and to neutralize these viruses.
Introduction

44
The highly specific interaction of the HIV envelope spike, a trimer composed of gp120 and gp41 45 heterodimers, with the cellular receptor CD4 and a co--receptor (typically CCR5 or CXCR4) 46 initiates HIV entry and is indispensable for infection (reviewed in (1)). Although, the potential of 47 HIV entry blocking agents for intervention strategies has been acknowledged for long and a domains are positioned facing inwards in the trimeric complex, only to be exposed transiently 58 upon receptor engagement (6--8), while the outer trimer surface is protected by flexible, 59 variable loops and extensive glycosylation (7, 9--11). These strategies act in concert to shield the 60 envelope complex from immune recognition and inhibitor attack (8, 12). Most of the gp120 61 outer domain is functionally not important (7, 13) and allows the virus to rapidly mutate and 62 evade any envelope targeting agent (12). Antibody--based vaccines and entry inhibitors thus 63 need to act against a wide spectrum of genetically divergent HIV strains to be effective, ideally 64 by targeting conserved, yet easily accessed sites on the viral envelope, which are important for 4 to develop DARPins specific for CD4, which proved to be highly potent in inhibiting entry of antibodies, most noteworthy their high target specificity and affinity, DARPins differ from 77 antibodies in size, structure and preference for folded proteins as targets (19). In the current 78 study we sought to explore whether these distinct properties of DARPins allow selection of 79 binding molecules which recognize epitopes on gp120 differing from those targeted by 80 antibodies and, which upon binding to virions, interfere with HIV entry. 81 To this end, we performed four independent series of ribosome display selections of gp120--82 specific DARPins, utilizing different gp120 molecules and epitope display approaches ( Figure 1A , 83 B). Our selections yielded a variety of gp120--directed DARPin molecules which all proved to 84 depend to a higher degree on a structural conservation of the envelope protein than gp120-- as described by the manufacturer (Invitrogen, USA). Gp120 was purified from culture 130 supernatants using Galantus nivalis lectin resin (Vector Laboratories) as described (35).
131
Retrieved gp120 was mono--biotinylated using BirA as described by the manufacturer (Roche) 132 followed by Superdex200 size exclusion chromatography (GE Healthcare, USA) to derive 133 monomeric gp120. To obtain deglycosylated gp120, 500 μg of gp120 were subjected to 0.15 U The number of selection rounds performed in each respective selection is stated in Figure  1B . were screened by binding ELISA as described above. NAB10pre--cl_2 and NAB12pre--cl_7 (50), ZA110.C.10.14 and V1V2--deleted envs (21 Selection of gp120 specific DARPin molecules 273 The high structural flexibility of the surface unit gp120 within the viral envelope trimer and its and 1 clone in Selection IV) with low reactivity with gp120 were detected, these had, however, 309 too low affinity (>10µM) for gp120 to allow further follow--up analysis (data not shown). however, V3 loop antibodies display remarkable potency and cross reactivity (21).
503
DARPin 5m3_D12 is thus able to partially circumvent V1V2 shielding. Intriguingly, we observed 504 a notable capacity of DARPin 5m3_D12 in blocking divergent strains of wild--type HIV ( Figure 5 ).
505
However, while our data suggest that 5m3_D12 is able to partially pass by the V1V2 shielding 506 on genetically divergent isolates, the activity of 5m3_D12 against viruses lacking the V1V2 507 domain was still markedly enhanced, indicating that access of 5m3_D12 is also to some extent 508 restricted by the V1V2 shield.
509
We next compared the neutralization breadth of 5m3_D12 to V3--specific mAbs 447--52D ( came from, while gp120--specific antibodies recognized the same mutant proteins unless their 566 epitope was known to be directly affected by the inferred mutations (Figure 4 ).
567
Preferences regarding specific gp120 conformations were also apparent amongst DARPins 568 selected against CD4M47--liganded gp120. Only the V3--loop--specific N3C clone 5m3_D12 was Selection III and 1 clone in Selection IV with borderline reactivity for gp120 were detected which 890 had, however, too low an affinity ( >10µM) for further analysis. 
